Results 151 to 160 of about 541,152 (293)
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance +17 more
wiley +1 more source
Prognostic disclosure in metastatic breast cancer: a scoping review. [PDF]
Battistuzzi L +3 more
europepmc +1 more source
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He +17 more
wiley +1 more source
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang +10 more
wiley +1 more source
Influence of Hypertension Management on Survival in Patients With Metastatic Breast Cancer. [PDF]
Haque R +8 more
europepmc +1 more source
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source
Metastatic breast cancer presenting with dyspeptic symptoms: a case report. [PDF]
Bekai C, Stirling M.
europepmc +1 more source
To combat BET inhibitor resistance in triple‐negative breast cancer, we developed two single‐cell computational frameworks. FR20 quantifies resistance by integrating ferroptosis‐related gene signatures, while D‐FR20 screens for potential re‐sensitizers.
Haizhou Liu +6 more
wiley +1 more source
Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer. [PDF]
Chiddarwar T, Blaes A, Kuntz K.
europepmc +1 more source

